Dr. Sanja Pekovic, Chief Project Scientist of HTDS, said, “The Datamonitor Group (http://www.datamonitor.com/) is world leader in the business intelligence sector. We expect that the multiple sclerosis and traumatic brain injury pipeline and unmet analysis needs of these two markets, prepared by Datamonitor’s healthcare and pharmaceutical analysis team, will provide us with insight into most recent findings in order to be a step ahead to our competitors. After getting permission, complete material comprising of clinical opinion, leader intelligence, best-in-class case studies, R&D pipeline, unmet need analysis, scenario-based revenue, epidemiology forecasting, a slide pack and a data pack covering seven major markets (US, France, Germany, Italy, Spain, UK, and Japan) will be available at the HTDS (http://www.htdsmedical.com) and Slavica BioChem (www.slavicabiochem.com) web sites.

About Mina Mar Group:

Mina Mar Group (MMG) is a corporate consultancy firm that specializes in small cap or OTC market business services, including public markets in Frankfurt, Germany, and the UK. We provide our clients with comprehensive advisory and consulting services regarding mergers and acquisitions, including reverse mergers of private companies into publicly traded entities, and special purpose companies (SPC) offshore. MMG also offers a full suite of related ancillary services subsequent to the successful completion of a reverse merger, including private placements, Pink Sheets Adequate Disclosure documentation, various SEC regulatory filings and a broad range of other corporate governance matters. Mina Mar Marketing Group, MMMG (www.minamargroup.net), offers publicly traded companies full array of services such as Investor Relations and maintenance investor awareness. Mina Mar Group pioneered the “Go Public Free” program, the first firm to challenge the short sellers, stock bashers and repeal of the “Communication Decency Act”. Visit www.minamargroup.com/ice to learn more.

Filings for this event are currently being reviewed and will be filed with Pink Sheets and Client Support section in due course. To be included in company’s email database for press releases, “Friday Tips” industry updates, and non-weekly activity in the company that may or may not be news released, please subscribe for opt in mailer at http://www.minamargroup.com/updates.

Safe Harbor Statement

Information in this filing may contain statements about future expectations, plans, prospects or performance of Hard to Treat Diseases, Inc. that constitute forward-looking statements for purposes of the safe harbor Provision’s under the Private Securities Litigation Reform Act of 1995. The words or phrases “can be,” “expects,” “may affect,” “believed,” “estimate,” “project,” and similar words and phrases are intended to identify such forward-looking statements. HTDS Corporation cautions you that any forward-looking information provided by or on behalf of Hard to Treat Diseases, Inc. is not a guarantee of future performance. None of the information in this filing constitutes or is intended as an offer to sell securities or investment advice of any kind. Hard to Treat Diseases, Inc.’s actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hard to Treat Diseases, Inc.’s control. In addition to those discussed in Hard to Treat Diseases, Inc.’s press releases, public filings, and statements by Hard to Treat Diseases, Inc.’s management, including, but not limited to, Hard to Treat Diseases, Inc.’s estimate of the sufficiency of its existing capital resources, Hard to Treat Diseases, Inc.’s ability to raise additional capital to fund future operations, HTDS Corporation’s ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities and, in identifying contracts which match Hard to Treat Diseases, Inc.’s capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Hard to Treat Diseases, Inc. does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.

SOURCE: http://www.marketwatch.com/story/hard-to-treat-diseases-inc-htds-step-ahead-of-competition-2010-07-22?reflink=MW_news_stmp

GROWTH believes the acquisition endows the Company with a portfolio of technologies with transformational potential. GROWTH’s business plan is to commercialize, license or sell the technologies as they mature. In connection with the LABS acquisition agreement, the Company granted Bulova Technologies Group, Inc. a first right of refusal with respect to defense technologies.

The technologies are concentrated in the following fields:

Defense
Alternative Energy
Alternative Healthcare
Healthcare Information
Construction and Building Materials

To date, there have been substantial investments in these technologies. The Company believes the future investment needed prior to commercialization, licensing or sale will not represent a significant financial burden.

About Growth Technologies International, Inc.

Headquartered in Clearwater, FL, Growth Technologies International, Inc. focuses on disruptive technologies in the fields of defense, alternative energy, alternative healthcare, healthcare information, and construction and building materials. The technologies have in common a focus on improving not only the business model but also on improving quality of life and sustainability.

Statements about the Company’s future expectations and all other statements in this press release other than historical facts, are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995. The Company intends that such forward-looking statements be subject to the safe harbors created thereby. The above information contains information relating to the Company that is based on the beliefs of the Company and/or its management as well as assumptions made by and information currently available to the Company or its management.

SOURCE: http://www.marketwatch.com/story/growth-technologies-international-inc-acquires-bulovatech-labs-2010-06-29?reflink=MW_news_stmp

About Protocall Technologies Protocall Technologies, Inc.’s (PINKSHEETS: PCLI) chief asset is Integrated Armor Systems (IAS) that specializes in the design and manufacturing of a wide array of ballistic, blast, and Improvised Explosive Device (IED) resistant and protective products.

IAS is a U.S. Army Certified (Aberdeen, MD, April, 2008) manufacturer of a patented & proprietary, prefabricated, portable, self contained IED Defeat System(s) and Bomb Blast Mitigation System(s) for both new and pre-existing IT Buildings, bunkers, structures, and Hard Asset Enclosures.

IAS manufactures a vast assortment of IED resistant and ballistic protected “armored” vehicles and vehicle seats; ranging from domestic and imported passenger vehicles, SUV, SWAT, Military, and Specialty Vehicles.

The company’s website can be found at http://intergratedarmor.com . The company’s main manufacturing facility and corporate headquarters are located in Dallas Texas at 11567 Hillguard Rd. Shareholders can reach the company for further information by calling (214) 221-4469.

Source: http://www.marketwatch.com/story/protocall-technologies-places-new-board-president-and-ceo-2010-06-25?reflink=MW_news_stmp

“Picking the best penny stocks is not rocketing science or brain surgery, but it just the study of certain performance parameters of successful companies. In short, it appears complicated as it is not an exact science as the first two mentioned activities are.  You will be surprised to know that a slew of cross-currents go into picking the best penny stocks. This information is not available on any website on penny stock investment and we will tell you also what the websites do not tell you.  There are certain facts that are considered in the activity of picking the best penny stocks.

Recent Gains:  Multiple times, we scan the NASDAQ, NYSE, AMEX, etc, and zero in on some stocks which are quoting at below $5.00, but they are recording the best percentage gains.  Track them for a few days to see if they have legs and if they are moving, and if yes then what moved them.

The Balance Sheet: Pretend that picking the best penny stock is nothing short of creating the Universe.  Look upon the Balance Sheet as the Big Bang,  Assess the liquidity position of the company for the next one year,  or are there too many liabilities in the balance sheet that cannot be covered by its assets?  If you find that the balance sheet seems sound then half the work is done.

Analysts Ratings:  There provide some comfort, although their opinion does not carry much weight in our eyes.

Institutional Ownership:  This factor is important only for companies which are being leveraged by brokerages, in which case they will want to see the company succeed at any cost.  Hence not much weightage is given to this point by us.

The Story: The Company’s business should be easy to understand and should not be rocket science. Assess the sector of the company and ascertain whether that sector is currently performing well.  In case if the company is into high tech then what kind of proprietary framework do they have and the number of patents that they have filed.  Recent news reports give an idea of the current activities of the company and its sector.

Target Prices: You should put target prices on all stock picks.

Your Big Question: Do not bet the house down on penny stocks. Only 10-12% of your money should go into the best penny stocks.  “